AI Article Synopsis
Article Abstract
Chemical modification of known, effective drugs is one method to improve chemotherapy. Thus, the object of this study was to generate melphalan derivatives with improved cytotoxic activity in human cancer cells (RPMI8226, HL60 and THP1). Several melphalan derivatives were synthesised, modified in their two important functional groups. Nine analogues were tested, including melphalan compounds modified: only at the amino group, by replacing the amine with an amidine group containing a morpholine ring (MOR-MEL) or with an amidino group and dipropyl chain (DIPR-MEL); only at the carboxyl group to form methyl and ethyl esters of melphalan (EM-MEL, EE-MEL); and in a similar manner at both functional groups (EM-MOR-MEL, EE-MOR-MEL, EM-DIPR-MEL, EE-DIPR-MEL). Melphalan derivatives were evaluated for cytotoxicity (resazurin viability assay), genotoxicity (comet assay) and the ability to induce apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labelling, TUNEL, phosphatidylserine externalisation, chromatin condensation, activity of caspases 3/7, 8 and 9 and intracellular concentration of calcium ions) in comparison with the parent drug. Almost all derivatives, with the exception of MOR-MEL and DIPR-MEL, were found to be more toxic than melphalan in all cell lines evaluated. Treatment of cultures with the derivatives generated a significant higher level of DNA breaks compared to those treated with melphalan, especially after longer incubation times. In addition, all the melphalan derivatives demonstrated a high apoptosis-inducing ability in acute monocytic and promyelocytic leukemia cells. This study showed that the mechanism of action of the tested compounds differed depending on the cell line, and allowed the selection of the most active compounds for further, more detailed investigations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066245 | PMC |
| http://dx.doi.org/10.1038/s41598-020-61436-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current and Emerging Immunotherapies for Systemic AL Amyloidosis.
Discov Med
September 2024
Department of Hematology-Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.
Article Synopsis
- Systemic light-chain (AL) amyloidosis is a rare condition caused by misfolded immunoglobulin light chains that accumulate in organs, leading to dysfunction and failure, especially when the heart is involved.* -
- Treatment primarily focuses on eliminating the abnormal plasma cell growth, with the current first-line therapy being a combination of four drugs known as DaraCyborD; some patients may require stem cell transplants if this approach is insufficient.* -
- Recent advancements include the use of monoclonal antibodies, like CAEL 101 and Birtamimab, aimed at breaking down amyloid deposits in affected organs, currently being tested in phase 3 trials for patients with significant cardiac involvement.*
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Lancet Haematol
November 2024
Department of Haematology, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Article Synopsis
- The study evaluates the effectiveness of a treatment regimen (ixazomib, thalidomide, and dexamethasone) followed by maintenance with ixazomib after salvage autologous hematopoietic stem-cell transplantation (HSCT) for patients with relapsed multiple myeloma, compared to observation.
- Conducted as part of a larger trial (Myeloma XII) across 79 UK hospitals, it involved patients aged 18+ with measurable disease and certain health criteria, randomized into two treatment groups.
- The primary measurement for effectiveness was progression-free survival, with safety assessments also being conducted, and a total of 206 patients participated in this phase of the trial.
The emerging role of melflufen and peptide-conjugates in multiple myeloma.
Curr Opin Oncol
November 2024
Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Purpose Of Review: The past two decades have witnessed an impressive expansion in the treatment landscape of multiple myeloma, leading to significant improvements in progression-free; as well as overall survival. However, almost all patients still experience multiple relapses during their disease course, with biological and cytogenetic heterogeneity affecting response to subsequent treatments. The purpose of this review is to provide a historical background regarding the role of alkylating agents and an updated data regarding the use of peptide-drug conjugates such as melflufen for patients with multiple myeloma.
View Article and Find Full Text PDFUnrelated cord blood transplantation using minimal-intensity conditioning in a 1.5-month-old infant with X-linked severe combined immunodeficiency.
Transpl Immunol
December 2024
Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
Article Synopsis
- - Severe combined immunodeficiency (SCID) requires early hematopoietic stem cell transplantation (HSCT) to restore immune function, but intense conditioning can worsen infections in infants, necessitating a gentler approach to minimize risks.
- - An infant diagnosed with X-linked SCID underwent unrelated cord blood transplantation (CBT) using a reduced intensity conditioning regimen, which led to successful reconstitution of B-cell functions and control of a pre-existing cytomegalovirus infection.
- - Five years later, the patient showed effective immunity post-vaccination, discontinued immunoglobulin therapy, and experienced normal growth and psychomotor development, indicating a successful outcome of the CBT procedure.
Fludarabine Melphalan, Reduced-dose Busulfan Versus Fludarabine, Melphalan, Full-dose Busulfan in Patients Receiving Cord Blood Transplantation.
Transplant Proc
October 2024
Department of Medicine, Division of Hematology, Showa University School of Medicine, Shinagawa-Ku, Tokyo, Japan. Electronic address:
Article Synopsis
- This study compares two chemotherapy regimens used in patients undergoing umbilical cord blood transplantation: Flu/Mel/Bu2 (lower busulfan dose) and Flu/Mel/Bu4 (higher busulfan dose).
- Researchers analyzed data from 87 adult patients to see if there were differences in nonrelapse mortality, relapse rates, progression-free survival, and overall survival between the two regimens.
- The results showed no significant differences in outcomes, suggesting that the Flu/Mel/Bu2 regimen is a safe and effective option, particularly for older patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!